ABX464 Emerging Drug Insight

Key Factors Driving ABX-464 Growth

1. Strong Phase III efficacy in ulcerative colitis de-risks commercialization

ABX-464’s biggest value driver is its successful Phase III induction data in moderate-to-severe ulcerative colitis (UC). In July 2025, Abivax announced that 50 mg once daily achieved a pooled 16.4% placebo-adjusted clinical remission rate at Week 8, meeting both the primary endpoint and all key secondary endpoints in the ABTECT-1 and ABTECT-2 trials. This significantly de-risks regulatory approval and makes obefazimod one of the most promising late-stage oral UC assets.

Sales implication: Late-stage UC assets with differentiated profiles can achieve >USD 1 billion annual sales, and some analysts project peak sales around USD 4 billion globally if Phase III maintenance data and approval are successful.

2. Novel first-in-class mechanism offers differentiation in a crowded IBD market

Obefazimod is a first-in-class oral miR-124 enhancer, unlike biologics or JAK inhibitors currently used in UC. By upregulating microRNA-124, it suppresses inflammatory pathways broadly while avoiding direct cytokine inhibition. This novel mechanism may improve physician adoption, especially for patients who fail anti-TNF or JAK therapies.

This differentiation is commercially important because most UC therapies are mechanistically crowded (TNF, IL-23, JAK), whereas ABX-464 offers novel sequencing potential.

 

3. Durable long-term efficacy supports chronic-use revenue

Long-term data are a major growth driver in chronic inflammatory diseases. Abivax reported that after 2 years of maintenance treatment, obefazimod maintained favorable efficacy and safety outcomes in UC patients, suggesting durable remission benefits—critical for long-term patient retention and payer support.

 

4. Large Phase III program strengthens regulatory confidence

Abivax’s Phase III ABTECT program enrolled 1,275 patients across 36 countries, making it one of the largest Phase III UC programs conducted for an oral therapy. Nearly 47.3% of participants had prior advanced therapy failure, showing efficacy in difficult-to-treat populations. This broad dataset improves regulatory confidence and supports favorable labeling.

This is important because strong Phase III breadth can accelerate uptake by positioning the drug for both biologic-naïve and biologic-experienced patients.

 

5. Oral administration gives ABX-464 a major commercial advantage

Obefazimod is an oral once-daily therapy, giving it a significant edge over injectable biologics like anti-TNFs and IL-23 inhibitors. Oral administration improves patient convenience, compliance, and market penetration, especially in moderate disease settings where physicians may prefer to delay biologics.

 

ABX-464 Recent Developments

New interim data from an open-label maintenance trial of obefazimod in ulcerative colitis (UC) patients highlight its long-term efficacy and favorable safety profile. In September 2023, the analysis evaluated step-down dosing from 50 mg to 25 mg for the third and fifth years of treatment.

Patients had received oral, once-daily obefazimod for approximately four years in the Phase IIa trial and two years in the Phase IIb trial, with eligibility requiring a Mayo endoscopic subscore of 0 or 1. Of 71 eligible patients switched to 25 mg, 63 completed the 48-week visit. Among completers, 53 (84%) achieved disease control, defined as stable or improved Modified Mayo Score. No new safety signals emerged in patients treated up to five years. 

 

“ABX-464 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ABX-464 for potential indication like Ulcerative colitis, COVID 2019 infections, Crohn’s disease, Rheumatoid arthritis, and Inflammatory bowel diseases in the 7MM. A detailed picture of ABX-464’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ABX-464 for potential indications. The ABX-464 market report provides insights about ABX-464’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ABX-464 performance, future market assessments inclusive of the ABX-464 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ABX-464 sales forecasts, along with factors driving its market.

 

ABX-464 Drug Summary

ABX-464 is an investigational, first-in-class oral small molecule developed by Abivax for the treatment of chronic inflammatory diseases, particularly ulcerative colitis. It acts through a unique mechanism by upregulating microRNA-124 (miR-124), a natural anti-inflammatory regulator that suppresses multiple pro-inflammatory cytokine pathways, thereby reducing intestinal inflammation without directly targeting a single cytokine or receptor. Administered as a once-daily oral therapy, obefazimod has demonstrated clinically meaningful efficacy and a favorable safety profile in Phase II and Phase III trials, including the ABTECT studies in moderate-to-severe ulcerative colitis, with evidence of sustained remission in long-term extension studies. Its novel mechanism, combined with oral convenience and potential broad immunomodulatory effects, positions it as a promising alternative to biologics and JAK inhibitors, with ongoing development programs exploring its use in other inflammatory conditions such as Crohn’s disease. The report provides ABX-464’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

 

Scope of the ABX-464 Market Report

The report provides insights into:

• A comprehensive product overview including the ABX-464 MoA, description, dosage and administration, research and development activities in potential indication like Ulcerative colitis, COVID 2019 infections, Crohn’s disease, Rheumatoid arthritis, and Inflammatory bowel diseases.
• Elaborated details on ABX-464 regulatory milestones and other development activities have been provided in ABX-464 market report.
• The report also highlights ABX-464‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ABX-464 market report also covers the patents information, generic entry and impact on cost cut.
• The ABX-464 market report contains current and forecasted ABX-464 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ABX-464 market report also features the SWOT analysis with analyst views for ABX-464 in potential indications.

 

Methodology

The ABX-464 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

ABX-464 Analytical Perspective by DelveInsight

In-depth ABX-464 Market Assessment

This ABX-464 sales market forecast report provides a detailed market assessment of ABX-464 for potential indication like Ulcerative colitis, COVID 2019 infections, Crohn’s disease, Rheumatoid arthritis, and Inflammatory bowel diseases in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ABX-464 sales data uptil 2034.

 

ABX-464 Clinical Assessment

The ABX-464 market report provides the clinical trials information of ABX-464 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ABX-464 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

 

ABX-464 Market Potential & Revenue Forecast

• Projected market size for the ABX-464 and its key indications
• Estimated ABX-464 sales potential (ABX-464 peak sales forecasts)
• ABX-464 Pricing strategies and reimbursement landscape

 

ABX-464 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ABX-464 Market positioning compared to existing treatments
• ABX-464 Strengths & weaknesses relative to competitors

 

ABX-464 Regulatory & Commercial Milestones

• ABX-464 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

 

ABX-464 Clinical Differentiation

• ABX-464 Efficacy & safety advantages over existing drugs
• ABX-464 Unique selling points

 

ABX-464 Market Report Highlights

• In the coming years, the ABX-464 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ABX-464 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ABX-464’s dominance.
• Other emerging products for Ulcerative colitis, COVID 2019 infections, Crohn’s disease, Rheumatoid arthritis, and Inflammatory bowel diseases are expected to give tough market competition to ABX-464 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ABX-464 in potential indications.
• Analyse ABX-464 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ABX-464 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ABX-464 in potential indications.

 

Key Questions Answered In The ABX-464 Market Report:

• What is the class of therapy, route of administration and mechanism of action of ABX-464? How strong is ABX-464’s clinical and commercial performance?
• What is ABX-464’s clinical trial status in each individual indications such as Ulcerative colitis, COVID 2019 infections, Crohn’s disease, Rheumatoid arthritis, and Inflammatory bowel diseases and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ABX-464 Manufacturers?
• What are the key designations that have been granted to ABX-464 for potential indications? How are they going to impact ABX-464’s penetration in various geographies?
• What is the current and forecasted ABX-464 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ABX-464 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to ABX-464 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ABX-464? What is the duration of therapy and what are the geographical variations in cost per patient?